Glioma clinical trials report from VPA Research provides comprehensive analysis and trends in global Glioma disease clinical trials. The research work analyzes the evolution of Glioma clinical trial trends across countries and regions.
The report focuses on drugs and therapies being evaluated for Glioma treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.
Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Glioma clinical trials.
Major drugs under development in Glioma are provided in the report along with their details of Mechanism of Action, Route of Administration, Target, therapy, molecule and class.
Scope of the Report- - Number of Glioma clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas
- Trial information by Phase and Subjects recruited
- Trial information by status, type, sponsor type
- Drugs used for treatment of Glioma
- Both observational and interventional trials analyzed
- Success rates of trials are analyzed
- Trends in enrollment over the past ten years identified
- Leading sponsors of Glioma clinical trials worldwide are listed
Reasons to Buy- - Track competition and design competitive advantages
- Identify right partners to associate with for further research
- Evaluate potential opportunities available in further clinical trials of the disease
- Formulate business development strategies through success rates of clinical trials
- Identify quick markets for recruiting subjects based on trials count by each market
Glioma- The condition occurs when the glial cells in the brain are affected and account for around one-third of all brain tumors. On the basis of location, these are classified as supratentorial (above tentorium) and infratentorial (below tenotrium).
On the basis of pace of development, these are categorized as Low grade (grades 1 and 2) and high grade (3 and 4). Treatment options vary with the grade of the disease, but most often it includes a combination of medicine, surgery, radiation and chemo therapies.
Malignant Glioma- Malignant Glioma is the most regular subtypes of glioma condition occurring in patients aged between 60 and 80. The condition is classified as grade 3 and grade 4, which comprises anaplastic high-grade gliomas and glioblastomas respectively.
High Grade Glioma- Malignant or high-grade glioma tumors are categorized as Grade 3 and Grade 4. Of this Grade 3 tumor types include- Anaplastic astrocytoma- The rare disease type comprises an estimated one-third of all astrocytoma types. Often observed in older persons, the condition can occur in any aged person. Astrocytoma emerges from star shaped cells in the brain, called astrocytes.
Anaplastic oligodendroglioma- It is a rare type of malignant tumor occurring mainly between 45 and 50 years of age. They possess abnormal genetic material and unique molecular, clinical, and histological characteristics and are important to diagnose.
Anaplastic oligoastrocytoma- Oligoastrocytoma occurs when either oligodendrocytes and astrocytes or both grow rapidly, causing formation of tumors in the brain. The term ‘Anaplastic’ refers to condition when tumor can spread into nearby tissues. They occur in Cerebrum area.
Anaplastic ependymoma- The fast growing subtype occurs primarily in posterior fossa part. The tumor cells show rapid growth pace and are associated with a less favorable prognosis and have higher possibility to infiltrate around the brain or disseminate into cerebrospinal fluid resulting in drop metastases.
Glioblastoma- The grade 4 type condition is further classified as primary and secondary types. The primary subtype occurs without earlier diagnosis of low grade tumors while the secondary type arouses from development of grade 2 or 3 subtypes. Tumor occurs as a result of accumulation of different mutations.
Pontine Gliomas- Diffuse intrinsic pontine glioma (DIPG) is an aggressive type of malignant glioma, arising from glioma tissue. As these are observed in the bottom area of the brain, they are tough to be treated. It is observed mostly in children.
Low Grade Glioma (LGGs) or often referred to as Grade-1 and 2 tumors, arouse from brain cells including astrocytes and oligodendrocytes. Causing mild and large seizures, the Glioma type is treated through a combination of surgery, chemotherapy, and radiation on the basis of disease condition. The condition is primarily observed in young and healthy individuals. Compared to high grade Glioma, these patients survive for long periods and lead quality life as this is a slow growth disease.
On the basis of appearance under microscope and genetic modifications, Low grade gliomas are classified as- Pilocytic astrocytomas — Observed in adults aging less than 25 and progresses very slowly compared to other types
Diffuse astrocytomas — Most observed subtype of low-grade glioma. Late 30’s individuals are the most affected age. Type of modification in IDH isocitrate-dehydrogenase gene determines the sub-types of Diffuse astrocytomas.
Oligodendrogliomas — Slow growing tumors, having mutation in the IDH gene in terms of missing 1p and 19q chromosomes.
Gangliogliomas — Posesses both gliomas and tumor related characteristics
Our reports have been used by over 10K customers, including:
Anaplastic Thyroid Cancer (Oncology) - Drugs in Development, 2021 Summary Anaplastic Thyroid Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Anaplastic Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development...
Papillary Thyroid Cancer (Oncology) - Drugs in Development, 2021 Summary Papillary Thyroid Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Papillary Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development...
Vulvar Cancer (Oncology) - Drugs in Development, 2021 Summary Vulvar Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Vulvar Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vulvar Cancer, complete...
Urethral Cancer (Oncology) - Drugs in Development, 2021 Summary Urethral Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Urethral Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Urethral Cancer, complete...
Cells Expressing Wilms Tumor Protein (WT33 or WT1) - Drugs in Development, 2021 Summary Cells Expressing Wilms Tumor Protein (WT33 or WT1) - Drugs in Development, 2021 provides in depth analysis on Cells Expressing Wilms Tumor Protein (WT33 or WT1) targeted pipeline therapeutics. The report provides...
Serine/Threonine Protein Kinase B Raf (p94 or Proto Oncogene B Raf or v Raf Murine Sarcoma Viral Oncogene Homolog B1 or BRAF or EC 126.96.36.199) - Drugs in Development, 2021 Summary Serine/Threonine Protein Kinase B Raf (p94 or Proto Oncogene B Raf or v Raf Murine Sarcoma Viral Oncogene Homolog B1 or...
Retinoblastoma Treatment Market Report Overview Retinoblastoma Treatment market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Retinoblastoma Treatment market types and applications. It is a focused study on Retinoblastoma Treatment market...
Sarcoma Drugs Market Report Overview Sarcoma Drugs market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Sarcoma Drugs market types and applications. It is a focused study on Sarcoma Drugs market space including global and regional eight-year...
Melanoma - Epidemiology Forecast to 2029
Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of the skin (World Health Organization, 2017).Melanocytes are embryological derivatives of neural crest tissue, and...
175 pages •
By Global Industry Analysts
• Apr 2021
- Global Myelodysplastic Syndrome (MDS) Drugs Market to Reach $3.2 Billion by 2027
- Amid the COVID-19 crisis, the global market for Myelodysplastic Syndrome (MDS) Drugs estimated at US$1.8 Billion in the year 2020, is projected to reach a revised size of US$3.2 Billion by 2027, growing at a CAGR of 8.4%...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.